TWI924633B - 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 - Google Patents

用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Info

Publication number
TWI924633B
TWI924633B TW109108366A TW109108366A TWI924633B TW I924633 B TWI924633 B TW I924633B TW 109108366 A TW109108366 A TW 109108366A TW 109108366 A TW109108366 A TW 109108366A TW I924633 B TWI924633 B TW I924633B
Authority
TW
Taiwan
Prior art keywords
antibody
autoantibody
specific
day
treatment
Prior art date
Application number
TW109108366A
Other languages
English (en)
Chinese (zh)
Other versions
TW202102541A (zh
Inventor
丹尼爾 克隆克
雷納 博克斯哈默
斯特凡 哈特勒
斯特凡 斯泰德爾
天統 賈魯塔
Original Assignee
德商莫菲西斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商莫菲西斯公司 filed Critical 德商莫菲西斯公司
Publication of TW202102541A publication Critical patent/TW202102541A/zh
Application granted granted Critical
Publication of TWI924633B publication Critical patent/TWI924633B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109108366A 2019-03-15 2020-03-13 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 TWI924633B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19163036.7 2019-03-15
EP19163036 2019-03-15

Publications (2)

Publication Number Publication Date
TW202102541A TW202102541A (zh) 2021-01-16
TWI924633B true TWI924633B (zh) 2026-05-11

Family

ID=65817862

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109108366A TWI924633B (zh) 2019-03-15 2020-03-13 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Country Status (12)

Country Link
US (1) US20220144965A1 (enExample)
EP (1) EP3938394A1 (enExample)
JP (2) JP7687956B2 (enExample)
KR (1) KR20220002891A (enExample)
CN (1) CN113574071B (enExample)
AU (2) AU2020242228B2 (enExample)
CA (1) CA3130132A1 (enExample)
IL (1) IL286343A (enExample)
MX (1) MX2021011181A (enExample)
SG (1) SG11202107319PA (enExample)
TW (1) TWI924633B (enExample)
WO (1) WO2020187718A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277930A1 (en) * 2021-01-14 2023-11-22 MorphoSys AG Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
TW202321303A (zh) * 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
CN116183930A (zh) * 2022-12-29 2023-05-30 陕西脉元生物科技有限公司 抗insrr抗体在制备检测和/或诊断神经系统相关疾病的产品中的应用
WO2026080575A1 (en) * 2024-10-08 2026-04-16 Human Immunology Biosciences, Inc. Anti-cd38 antibodies and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428444B (zh) * 2005-10-12 2014-03-01 莫菲西斯公司 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
HUE027683T2 (en) 2007-10-01 2016-10-28 Codexis Inc Ketoreductase polypeptides for the production of azetidinone
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
US8877899B2 (en) * 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HRP20171964T1 (hr) * 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN108699161B (zh) 2016-03-04 2022-06-03 莫佛塞斯公司 多发性骨髓瘤中m-蛋白应答的临床评估

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428444B (zh) * 2005-10-12 2014-03-01 莫菲西斯公司 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
;期刊 Laurence H Beck Jr et al., Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. doi: 10.1681/ASN.2010111125. 22(8): 2011 Aug; Epub 2011 Jul 22. 1543-1550.;期刊 Piero Ruggenenti et al., Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 13(9): doi: 10.1038/nrneph.2017.92. 2017 Sep; Epub 2017 Jul 3. 563-579.;期刊 Antoine Barbari, Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 13(11):720. doi: 10.1038/nrneph.2017.134. 2017 Nov; Epub 2017 Sep 25, Page 1. *
期刊 Antoine Barbari, Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 13(11):720. doi: 10.1038/nrneph.2017.134. 2017 Nov; Epub 2017 Sep 25, Page 1.
期刊 Laurence H Beck Jr et al., Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. doi: 10.1681/ASN.2010111125. 22(8): 2011 Aug; Epub 2011 Jul 22. 1543-1550.
期刊 Piero Ruggenenti et al., Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 13(9): doi: 10.1038/nrneph.2017.92. 2017 Sep; Epub 2017 Jul 3. 563-579.
期刊 魏昕等人， 膜性腎病診療進展， 江西醫藥， 第53卷第12期， 2018年12月， 第1355-1358頁 *
期刊 魏昕等人， 膜性腎病診療進展， 江西醫藥， 第53卷第12期， 2018年12月， 第1355-1358頁。

Also Published As

Publication number Publication date
TW202102541A (zh) 2021-01-16
CA3130132A1 (en) 2020-09-24
WO2020187718A1 (en) 2020-09-24
IL286343A (en) 2021-10-31
AU2020242228A1 (en) 2021-07-22
JP2022524204A (ja) 2022-04-28
KR20220002891A (ko) 2022-01-07
CN113574071A (zh) 2021-10-29
CN113574071B (zh) 2025-03-25
EP3938394A1 (en) 2022-01-19
AU2020242228B2 (en) 2025-12-11
NZ777838A (en) 2025-05-02
MX2021011181A (es) 2022-01-19
US20220144965A1 (en) 2022-05-12
AU2026201243A1 (en) 2026-03-12
JP2025126171A (ja) 2025-08-28
SG11202107319PA (en) 2021-08-30
JP7687956B2 (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
TWI784988B (zh) 治療發炎症狀的方法
JP7687956B2 (ja) 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
JP7420730B2 (ja) 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
JP7357120B2 (ja) シェーグレン症候群の治療に使用するための抗ｃｄ４０抗体
CN104800844A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
JP2023520516A (ja) 抗ｔｒｅｍ２抗体の使用方法
TW202346344A (zh) 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
CN108064169A (zh) 抗体、用途和方法
US20170002077A1 (en) Combination treatment for multiple sclerosis
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
JP2019528285A (ja) 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法
JP2023515478A (ja) 抗ｔｒｅｍ２抗体の使用方法
US20240109977A1 (en) Anti-cd38 antibodies and their uses
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
RU2809565C2 (ru) Антитела к CD38 и фармацевтические композиции на их основе для лечения аутоиммунного заболевания, опосредованного аутоантителами
JP2024504696A (ja) Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
HK40061358B (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20240043562A1 (en) Musk activation
HK40061358A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体